Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.47 |
| ▸ | THRA | P10827 | 17/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28442792 | 0.87 | THRB (0.56) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632821 | 0.84 | THRB (0.52) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL28651241 | 0.83 | THRB (0.51) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22633041 | 0.83 | THRB (0.66) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL25871739 | 0.82 | THRB (0.42) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23260625 | 0.79 | — | — | |
| SCHEMBL23260087 | 0.78 | MAPT (0.32) | — | |
| SCHEMBL23245111 | 0.76 | THRA (0.67) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632433 | 0.75 | THRB (0.63) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22643928 | 0.73 | THRB (0.65) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115022-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115022-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885CYP2C9 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.